Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032
Key Highlights
Non-metastatic prostate cancer (nmPC) refers to prostate cancer that has not spread beyond the prostate gland and nearby lymph nodes. It is a localized form of prostate cancer. When prostate cancer is diagnosed at this stage, it means that cancer cells are confined to the prostate and have not yet invaded surrounding tissues or metastasized (spread) to distant organs, such as bones, lungs, or liver.
Non-metastatic Prostate Cancer is typically diagnosed through a combination of tests, including prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), and prostate biopsies. Imaging techniques, such as multiparametric magnetic resonance imaging (mpMRI), may also be used to assess the extent and location of the cancer within the prostate.
The staging of prostate cancer helps determine the extent of the disease. Non-metastatic prostate cancer is typically categorized as stage I, stage II, or stage III, depending on factors like tumor size, involvement of nearby structures, and lymph node involvement. The cancer is considered localized within the prostate and nearby areas.
The choice of treatment for non-metastatic Prostate Cancer depends on various factors, including the patient's age, overall health, the aggressiveness of the cancer, and individual preferences. The treatment options include active surveillance, surgery, radiation therapy as well as hormone therapy.
While non-metastatic Prostate Cancer is localized, there is always a risk that it may progress to a more advanced stage, including metastatic prostate cancer. The goal of treatment and monitoring is to delay or prevent such progression.
Ongoing research and clinical trials aim to improve treatments for non-metastatic Prostate Cancer and may offer patients access to innovative therapies and treatment strategies.
The approved treatment options for non-metastatic prostate cancer include XTANDI, ERLEADA and NUBEQA.
Report Summary
The detailed report provides significant knowledge about epidemiological segments including the historical as well as forecasted patient pool data, thus providing a thorough picture of anticipated future development in diagnostic rates, disease progression, and treatment guidelines. It gives deep insights into various areas, allowing for a complete examination of the subject.
The report also includes an all-inclusive account of current management techniques and emerging therapies, as well as elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift. The therapy profiles include detailed assessment of the current and emerging therapies including information regarding the approval-based as well as ongoing trials along with thorough drug description. The report also includes surgery data as well. Detailed account of different surgical procedures has been provided in the report.
The report also encompasses a comprehensive analysis of Non-metastatic Prostate Cancer market, providing an in-depth examination of its historical and projected market size (2019–2032). It also includes the market share of therapies, along with detailed assumptions and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
The report includes qualitative as well as quantitative insights that provide an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey which gives an overview of the patient landscape commencing from detection of the disease to treatment being administered to the patients, with the treatment preferences that help shape and drive the 7MM Non-metastatic Prostate Cancer market.
Market
There are various key players currently investigating their drugs for Non-metastatic Prostate Cancer, such as Myovant Sciences, Kangpu Biopharmaceuticals, and Candel Therapeutics etc. The details of the country and therapy-wise market size have been provided below.
In the 7MM region, the United States was found to capture the largest market size in 2022. In 2022, the United States accounted for ~USD 3,200 million
Among the 7MM countries, Spain accounted for the smallest market size that is ~USD 150 million.
As far as the initial therapies are concerned, surgery accounted for the highest market size in 2022 that is ~ USD 1,300 million.
Among the therapies given to biochemical recurrence patients, systemic therapy garnered the largest market size that is around USD 260 million.
Non-metastatic Prostate Cancer Drug Chapters
The Non-metastatic Prostate Cancer report's drugs section includes an in-depth examination of marketed drugs as well as late-stage pipeline therapeutics (Phase III and Phase II) for Non-metastatic Prostate Cancer.
The drug chapters section contains useful information on various aspects of Non-metastatic Prostate Cancer clinical trials, including specific details such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. It also includes the most recent news updates and press releases on drugs that treat Non-metastatic Prostate Cancer.
Marketed Therapies
ERLEADA (apalutamide): Janssen Pharmaceutical
ERLEADA (apalutamide) is a next-generation oral AR inhibitor that blocks the androgen signaling pathway in prostate cancer cells. It is indicated for the treatment of patients with nmCRPC and with mCSPC. It is taken orally, once daily, with or without food. ERLEADA inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the AR, by stopping the AR from entering the cancer cells, and by preventing the AR from binding to the DNA of the cancer cell.
ORGOVYX (relugolix): Myovant Sciences
ORGOVYX (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the FDA for treating adult patients with advanced prostate cancer. As a GnRH antagonist, ORGOVYX blocks the GnRH receptor and reduces the production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer. Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and, consequently, testosterone
Note: Detailed assessment will be provided in the final report of Non-metastatic Prostate Cancer…
Emerging Therapies
CAN-2409: Candel Therapeutics
CAN-2409, Candel’s most advanced viral immunotherapy candidate, is a replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. The intra-tumoral administration results in the release of tumor-specific neoantigens in the microenvironment. At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, which is designed to create the optimal conditions to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor
Note: Detailed assessment will be provided in the final report of Non-metastatic Prostate Cancer…
Non-metastatic Prostate Cancer Market Outlook
Non-metastatic castration-sensitive prostate cancer is abbreviated as nmCSPC. It essentially refers to prostate cancer that has not migrated to other regions of the body and remains responsive to hormone treatment (ADT). The prevalence of mCSPC, the availability of effective therapies, evolving treatment recommendations, and the pharmaceutical sector's investment in research and development all have an impact on the market potential for nmCSPC.
With the development of cutting-edge drugs such as androgen receptor inhibitors (ARIs) such as ERLEADA (apalutamide), XTANDI (enzalutamide), and NUBEQA (darolutamide), the therapeutic landscape for nmCSPC has changed substantially. The approval of these drugs have broadened treatment choices beyond standard hormone therapy.
The traditional therapeutic method for nmCRPC patients, androgen deprivation therapy (ADT) alone until metastatic disease, is now thought to be inadequate. Several randomised Phase III clinical studies have shown considerable clinical advantages for therapies that combine ADT with apalutamide, enzalutamide, and darolutamide, including considerably improved overall survival (OS).
Metastasis-free survival (MFS) improvement in the PROSPER, SPARTAN, and ARAMIS studies supports the use of enzalutamide, apalutamide, and darolutamide in patients with nmCRPC. Because there have been no direct clinical trials comparing these three therapies, no single therapy can be established to be the best therapy in terms of clinical effectiveness or safety. In comparison to the placebo, each of these drugs has exhibited a fair safety and adverse event profile.
According to research presented at the ASCO Genitourinary Cancers Symposium (2023), it was found that patients with nmCRPC treated with NUBEQA (darolutamide) were less likely to develop metastatic disease or discontinue treatment due to adverse events than patients treated with XTANDI (enzalutamide) or ERLEADA (apalutamide).
Note: Detailed assessment will be provided in the final report of Non-metastatic Prostate Cancer…
Non-metastatic Prostate Cancer Understanding and Treatment
Non-metastatic Prostate Cancer Overview
Non-metastatic prostate cancer refers to prostate cancer that has not spread beyond the prostate gland and nearby lymph nodes. It is a localized form of prostate cancer. Prostate cancer is a highly endocrine-responsive disease. It re-lies profoundly on the androgen signaling pathway for its growth and survival.
Prostate cancer occurs when the DNA in cells in the prostate develops mutations that may disable their ability to control cell growth and division. In many cases, these mutated cells die or are attacked by the immune system. However, some mutated cells may escape the immune system and grow out of control, forming a prostate tumor
Detailed overview will be provided in the final report…
Non-metastatic Prostate Cancer Diagnosis
Screening is testing to find cancer in people before they have symptoms. However, It is unclear if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. If one of these test results is abnormal, patients will probably need a prostate biopsy to know the cancer occurrence.
Further details related to diagnosis are provided in the report…
Non-metastatic Prostate Cancer Treatment
Localized prostate cancer represents a paradox when left untreated; it is generally associated with a good prognosis. However, because prostate cancer is a common cause of cancer-related mortality, there is usually significant patient anxiety once the diagnosis is confirmed. All standard treatments carry risks of adverse events that might negatively impact short-, medium-, or long-term quality of life. As such, the clinical approach to managing localized prostate cancer must consider not only the disease features, such as stage, grade, and volume of cancer detected, but also patient comorbidities, life expectancy, and priorities.
The optimal management of localized prostate cancer starts with discussion by a multidisciplinary team (MDT) consisting of radiation oncologists, medical oncologists, urologists, histopathologists, radiologists, and specialist nurses. Each brings their expertise and knowledge of the patient to help determine which treatment options are appropriate for an individual.
Further details related to treatment and management are provided in the report…..
Non-metastatic Prostate Cancer Epidemiology
The Non-metastatic Prostate Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Non-metastatic Prostate Cancer, Total Age-specific Cases of Non-metastatic Prostate Cancer, Total Stage-specific Cases of Non-metastatic Prostate Cancer, Total Line-wise Treated Cases of Non-metastatic Prostate Cancer covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.
The total diagnosed prevalent cases of prostate cancer in the United States were ~1,409,000 in 2022. The cases are expected to increase by 2032.
In Japan, the highest number of cases of prostate cancer were found in the 65-74 years age group. The least number of patients belonged to the = 54 years age group.
The total stage-specific cases of prostate cancer in EU4 and the UK in 2022 were ~7,002,000 and ~490,000 cases for locally advanced (Stage I–III) and metastatic stage (Stage IV), respectively
Further details related to epidemiology will be provided in the report…
KOL Views
In order to stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.
We have reached out to industry experts to gather insights on various aspects of Non-metastatic Prostate Cancer, including the evolving treatment landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.
Our team of analysts at DelveInsight connected with more than 10 KOLs across the 7 Major Markets (7MM). We contacted institutions such as Duke University, University of Manchester, and others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Non-metastatic Prostate Cancer market, which will assist our clients in analyzing the overall epidemiology and market scenario.
Qualitative Analysis
We conduct qualitative and market intelligence analysis employing a variety of methods, including SWOT analysis and Conjoint Analysis. Strengths, weaknesses, opportunities, and threats in disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are described in the SWOT analysis. These recommendations are based on the Analyst's evaluation of the patient burden, cost analysis, and the current and emerging therapy landscape. Conjoint Analysis compares the effectiveness and safety of numerous approved and emergent drugs depending on key criteria such as frequency of administration, designation, route of administration, and order of entry. To assess the success of therapy, several factors are evaluated.
Furthermore, the drug's safety is analyzed, in which acceptability, tolerability, and adverse events are closely monitored, and it establishes a firm grasp of the side effects posed by the drugs used in the trials. Furthermore, for each therapy, the rating is based on the route of administration, sequence of entrance and designation, chance of success, and addressable patient pool. The ultimate weightage score and ranking of developing therapeutics are determined by these characteristics.
Market Access and Reimbursement
Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Non-metastatic Prostate Cancer Report Insights
Patient Population
Therapeutic Approaches
Line-wise market size of therapies
Non-metastatic Prostate Cancer Market Size and Trends
Existing Market Opportunity
Non-metastatic Prostate Cancer Report Key Strengths
Ten-year Forecast
The 7MM Coverage
Non-metastatic Prostate Cancer Epidemiology Segmentation (Segmented by age and stage-specific cases and line-wise treated cases)
Key Cross Competition evaluating the marketed as well as emerging therapies
Non-metastatic Prostate Cancer Report Assessment
Current Treatment and Management Practices
Unmet Needs
Market Attractiveness
Qualitative Analysis (SWOT, Conjoint Analysis)
Key Questions
Would there be any changes observed in the current treatment approach?
Will there be any improvements in Non-metastatic Prostate Cancer management recommendations?
Would research and development advances pave the way for future tests and therapies for Non-metastatic Prostate Cancer?
Would the innovations in diagnostic tests of Non-metastatic Prostate Cancer space experience a significant impact and lead to a positive shift in the treatment landscape of Non-metastatic Prostate Cancer?
What kind of uptake the new therapies are going to witness in the coming years in Non-metastatic Prostate Cancer patients?
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. NSCLC Market Overview at a Glance
- 4.1. Market Share (%) Distribution by Line of Therapies in 2019
- 4.2. Market Share (%) Distribution by Line of Therapies in 2032
- 5. Key Events
- 6. Epidemiology and Market Forecast Methodology
- 7. Disease Background and Overview
- 7.1. Introduction
- 7.1.1. Cellular Classification of NSCLC
- 7.1.2. Signs and Symptoms of NSCLC
- 7.1.3. Risk Factors of Lung Cancer
- 7.1.4. Causes of NSCLC
- 7.1.5. Disease Biology: NSCLC
- 8. Diagnosis of NSCLC
- 8.1. Stages of NSCLC
- 8.2. Staging System
- 9. Current Treatment Practices: NSCLC
- 9.1. Chemotherapy
- 9.2. Targeted Therapy
- 9.3. Immunotherapy
- 9.4. Surgery
- 9.5. Radiation Therapy
- 9.6. Stage-wise Treatment Options of NSCLC
- 10. Treatment Guidelines and Recommendations for Non-small Cell Lung Cancer (NSCLC)
- 10.1. NCCN Guideline for NSCLC
- 10.2. ESMO Guideline for Non-small Cell Lung Cancer (NSCLC)
- 10.2.1. Non-oncogene-addicted metastatic Non-small-cell lung cancer: ESMO Clinical Practice Guidelines for Treatment.
- 10.2.2. Oncogene-addicted Metastatic Non-small-cell Lung Cancer: ESMO Clinical Practice Guidelines for Treatment.
- 10.3. Japanese Guidelines for Non-small Cell Lung Cancer (NSCLC)
- 10.4. Biomarkers Testing Recommendations
- 11. Epidemiology and Patient Population
- 11.1. Key Findings
- 11.2. Assumptions and Rationale: The 7MM
- 11.3. Total Incident Cases of NSCLC in the 7MM
- 11.4. United States Epidemiology
- 11.4.1. Total Incident Cases of NSCLC in the United States
- 11.4.2. Gender-specific Cases of NSCLC in the United States
- 11.4.3. Age-specific Cases of NSCLC in the United States
- 11.4.4. Total Incident Cases of NSCLC by Histology in the United States
- 11.4.5. Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States
- 11.4.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States
- 11.5. EU4 and the UK
- 11.5.1. Total Incident Cases of NSCLC in EU4 and the UK
- 11.5.2. Gender-specific Cases of NSCLC in EU4 and the UK
- 11.5.3. Age-specific Cases of NSCLC in EU4 and the UK
- 11.5.4. Total Incident Cases of NSCLC by Histology in EU4 and the UK
- 11.5.5. Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK
- 11.5.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK
- 11.6. Japan Epidemiology
- 11.6.1. Total Incident Cases of NSCLC in Japan
- 11.6.2. Gender-specific Cases of NSCLC in Japan
- 11.6.3. Age-specific Cases of NSCLC in Japan
- 11.6.4. Total Incident Cases of NSCLC by Histology in Japan
- 11.6.5. Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan
- 11.6.6. Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan
- 12. Patient Journey
- 13. Key Endpoints in NSCLC
- 14. Marketed Drugs
- 14.1. Key Competitors
- 14.2. Gilotrif/GIOTRIF (Afatinib): Boehringer Ingelheim
- 14.2.1. Product Description
- 14.2.1. Regulatory Milestones
- 14.2.2. Other Developmental Activities
- 14.2.3. Pivotal Clinical Trial
- 14.2.4. Current Pipeline Activity
- 14.2.5. Safety and Efficacy
- 14.2.6. Product Profile
- 14.3. LIBTAYO (Cemiplimab): Regeneron/Sanofi
- 14.3.1. Product Description
- 14.3.2. Regulatory Milestones
- 14.3.3. Other Developmental Activities
- 14.3.4. Pivotal Clinical Trials
- 14.3.5. Current Pipeline Activity
- 14.3.6. Safety and Efficacy
- 14.3.7. Product Profile
- 14.4. TEPMETKO (Tepotinib): EMD Serono; Merck KGaA
- 14.4.1. Product Description
- 14.4.2. Regulatory Milestones
- 14.4.3. Other Developmental Activities
- 14.4.4. Pivotal Clinical Trial
- 14.4.5. Current Pipeline Activity
- 14.4.6. Safety and Efficacy
- 14.4.7. Product Profile
- 14.5. RETEVMO (Selpercatinib): Eli Lilly
- 14.5.1. Product Description
- 14.5.2. Regulatory Milestones
- 14.5.3. Other Developmental Activities
- 14.5.4. Pivotal Clinical Trial
- 14.5.5. Current Pipeline Activity
- 14.5.6. Safety and Efficacy
- 14.5.7. Product Profile
- 14.6. KEYTRUDA (Pembrolizumab): MSD
- 14.6.1. Product Description
- 14.6.2. Regulatory Milestones
- 14.6.3. Other Developmental Activities
- 14.6.4. Pivotal Clinical Trial
- 14.6.5. Current Pipeline Activity
- 14.6.6. Safety and Efficacy
- 14.6.7. Product Profile
- 14.7. RYBREVANT (amivantamab): Janssen
- 14.7.1. Product Description
- 14.7.2. Regulatory Milestones
- 14.7.3. Other Developmental Activities
- 14.7.4. Pivotal Clinical Trial
- 14.7.5. Current Pipeline Activity
- 14.7.6. Safety and Efficacy
- 14.7.7. Product Profile
- 14.8. EXKIVITY (mobocertinib): Takeda
- 14.8.1. Product Description
- 14.8.2. Regulatory Milestones
- 14.8.3. Other Developmental Activities
- 14.8.4. Pivotal Clinical Trial
- 14.8.5. Current Pipeline Activity
- 14.8.6. Safety and Efficacy
- 14.8.7. Product Profile
- 14.9. PORTRAZZA (necitumumab): Eli Lilly
- 14.9.1. Product Description
- 14.9.2. Regulatory Milestones
- 14.9.3. Other Developmental Activities
- 14.9.4. Pivotal Clinical Trial
- 14.9.5. Current Pipeline Activity
- 14.9.6. Safety and Efficacy
- 14.9.7. Product Profile
- 14 .9. OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical 191
- 14.9.8. Product Description
- 14.9.9. Regulatory Milestones
- 14.9.10. Other Developmental Activities
- 14.9.11. Pivotal Clinical Trial
- 14.9.12. Current Pipeline Activity
- 14.9.13. Safety and Efficacy
- 14.9.14. Product Profile
- 14.10. TECENTRIQ (atezolizumab): Genentech/Hoffmann-La Roche
- 14.10.1. Product Description
- 14.10.2. Regulatory Milestones
- 14.10.3. Other Developmental Activities
- 14.10.4. Pivotal Clinical Trial
- 14.10.5. Current Pipeline Activity
- 14.10.6. Safety and Efficacy
- 14.10.7. Product Profile
- 14.11. LORBRENA/LORVIQUA (lorlatinib): Pfizer
- 14.11.1. Product Description
- 14.11.2. Regulatory Milestones
- 14.11.3. Pivotal Clinical Trial
- 14.11.4. Current Pipeline Activity
- 14.11.5. Safety and Efficacy
- 14.11.6. Product Profile
- 14.12. GAVRETO (pralsetinib): Blueprint Medicines/Hoffmann-La Roche
- 14.12.1. Product Description
- 14.12.2. Regulatory Milestones
- 14.12.3. Other Developmental Activities
- 14.12.4. Pivotal Clinical Trial
- 14.12.5. Current Pipeline Activity
- 14.12.6. Product Profile
- 14.13. ALUNBRIG (brigatinib): Takeda Pharmaceuticals (ARIAD Pharmaceuticals)
- 14.13.1. Product Description
- 14.13.2. Regulatory Milestones
- 14.13.3. Other Developmental Activities
- 14.13.4. Pivotal Clinical Trial
- 14.13.5. Current Pipeline Activity
- 14.13.6. Safety and Efficacy
- 14.13.7. Product Profile
- 14.14. ALECENSA (Alectinib): Genentech/Hoffmann-La Roche/Chugai Laboratories
- 14.14.1. Product Description
- 14.14.2. Regulatory Milestones
- 14.14.3. Other Developmental Activities
- 14.14.4. Pivotal Clinical Trial
- 14.14.5. Current Pipeline Activity
- 14.14.6. Safety and Efficacy
- 14.14.7. Product Profile
- 14.15. IMFINZI (durvalumab): AstraZeneca
- 14.15.1. Product Description
- 14.15.2. Regulatory Milestones
- 14.15.3. Other Developmental Activities
- 14.15.4. Pivotal Clinical Trial
- 14.15.5. Current Pipeline Activity
- 14.15.6. Safety and Efficacy
- 14.15.7. Product Profile
- 14.16. LUMAKRAS/LUMYKRAS (sotorasib): Amgen
- 14.16.1. Product Description
- 14.16.2. Regulatory Milestones
- 14.16.3. Other Developmental Activities
- 14.16.4. Pivotal Clinical Trial
- 14.16.5. Current Pipeline Activity
- 14.16.6. Safety and Efficacy
- 14.16.7. Product Profile
- 14.17. KRAZATI (adagrasib): Mirati Therapeutics
- 14.17.1. Product Description
- 14.17.2. Regulatory Milestones
- 14.17.3. Other Developmental Activities
- 14.17.4. Pivotal Clinical Trial
- 14.17.5. Current Pipeline Activity
- 14.17.6. Safety and Efficacy
- 14.17.7. Product Profile
- 14.18. TABRECTA (capmatinib): Novartis
- 14.18.1. Product Description
- 14.18.2. Regulatory Milestones
- 14.18.3. Other Developmental Activities
- 14.18.4. Pivotal Clinical Trial
- 14.18.5. Current Pipeline Activity
- 14.18.6. Safety and Efficacy
- 14.18.7. Product Profile
- 14.19. ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo/AstraZeneca
- 14.19.1. Product Description
- 14.19.2. Regulatory Milestones
- 14.19.3. Other Developmental Activities
- 14.19.4. Pivotal Clinical Trials
- 14.19.5. Current Pipeline Activity
- 14.19.6. Safety and Efficacy
- 14.19.7. Product Profile
- 14.2. TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis
- 14.20.1. Product Description
- 14.20.2. Regulatory Milestones
- 14.20.3. Other Developmental Activities
- 14.20.4. Pivotal Clinical Trial
- 14.20.5. Product Profile
- 14.21. TAGRISSO (osimertinib): AstraZeneca
- 14.21.1. Product Description
- 14.21.2. Regulatory Milestones
- 14.21.3. Other Developmental Activities
- 14.21.4. Pivotal Clinical Trials
- 14.21.5. Current Pipeline Activity
- 14.21.6. Safety and Efficacy
- 14.21.7. Product Profile
- 14.22. VIZIMPRO (dacomotinib): Pfizer
- 14.22.1. Product Description
- 14.22.2. Regulatory Milestones
- 14.22.3. Other Developmental Activities
- 14.22.4. Pivotal Clinical Trials
- 14.22.5. Safety and Efficacy
- 14.22.6. Product Profile
- 14.23. ROZLYTREK (entrectinib): Roche (Genentech)
- 14.23.1. Product Description
- 14.23.2. Regulatory Milestones
- 14.23.3. Other Developmental Activities
- 14.23.4. Pivotal Clinical Trials
- 14.23.5. Product Profile
- 14.24. VITRAKVI (larotrectinib): Bayer/Loxo Oncology
- 14.24.1. Product Description
- 14.24.2. Regulatory Milestones
- 14.24.3. Other Developmental Activities
- 14.24.4. Pivotal Clinical Trials
- 14.24.5. Current Pipeline Activity
- 14.24.6. Safety and Efficacy
- 14.24.7. Product Profile
- 15. Emerging Drugs
- 15.1. Key Competitors
- 15.2. Ociperlimab: BieGene
- 15.2.1. Product Description
- 15.2.2. Other Developmental Activities
- 15.2.3. Clinical Development
- 15.2.4. Safety and Efficacy
- 15.3. Datopotamab Deruxtecan: Daiichi Sankyo/AstraZeneca
- 15.3.1. Product Description
- 15.3.2. Other Developmental Activities
- 15.3.3. Clinical Development
- 15.3.4. Safety and Efficacy
- 15.4. Domvanalimab: Arcus Biosciences
- 15.4.1. Product Description
- 15.4.2. Other Developmental Activities
- 15.4.3. Clinical Development
- 15.4.4. Safety and Efficacy
- 15.5. Tiragolumab: Hoffmann-La Roche/Genentech
- 15.5.1. Product Description
- 15.5.2. Other Developmental Activities
- 15.5.3. Clinical Development
- 15.5.4. Safety and Efficacy
- 15.6. Zejula (Niraparib): GlaxoSmithKline
- 15.6.1. Product Description
- 15.6.2. Other Developmental Activities
- 15.6.3. Clinical Development
- 15.6.4. Safety and Efficacy
- 15.7. Pyrotinib: Jiangsu HengRui Medicine
- 15.7.1. Product Description
- 15.7.2. Clinical Development
- 15.8. Volrustomig: AstraZeneca
- 15.8.1. Product Description
- 15.8.2. Other Developmental Activities
- 15.8.3. Clinical Development
- 15.9. Zimberelimab: Arcus Biosciences/Gilead Sciences
- 15.9.1. Product Description
- 15.9.2. Other Developmental Activities
- 15.9.3. Clinical Development
- 15.9.4. Safety and Efficacy
- 15.1. Fianlimab: Regeneron Pharmaceuticals
- 15.10.1. Product Description
- 15.10.2. Other Developmental Activities
- 15.10.3. Clinical Development
- 15.11. HLX10: Shanghai Henlius Biotech
- 15.11.1. Product Description
- 15.11.2. Other Developmental Activities
- 15.11.3. Clinical Development
- 15.12. Cobolimab: GlaxoSmithKline
- 15.12.1. Product Description
- 15.12.2. Other Developmental Activities
- 15.12.3. Clinical Development
- 15.13. BRAFTOVI (encorafenib) + MEKTOVI (binimetinib): Pfizer
- 15.13.1. Product Description
- 15.13.2. Other Developmental Activities
- 15.13.3. Clinical Development
- 15.13.4. Safety and Efficacy
- 15.14. Telisotuzumab Vedotin: AbbVie
- 15.14.1. Product Description
- 15.14.2. Other Developmental Activities
- 15.14.3. Clinical Development
- 15.14.4. Safety and Efficacy
- 15.15. Savolitinib: AstraZeneca
- 15.15.1. Product Description
- 15.15.2. Other Developmental Activities
- 15.15.3. Clinical Development
- 15.15.4. Safety and Efficacy
- 15.16. Taletrectinib (DS-6051b; AB-106): AnHeart Therapeutics
- 15.16.1. Product Description
- 15.16.2. Other Developmental Activities
- 15.16.3. Clinical Development
- 15.16.4. Safety and Efficacy
- 15.17. Repotrectinib (TPX-0005): Bristol-Myers Squibb
- 15.17.1. Product Description
- 15.17.2. Other Developmental Activities
- 15.17.3. Clinical Development
- 15.17.4. Safety and Efficacy
- 15.18. NVL-520: Nuvalent
- 15.18.1. Product Description
- 15.18.2. Other Developmental Activities
- 15.18.3. Clinical Development
- 15.18.4. Safety and Efficacy
- 15.19. Zipalertinib (CLN-081/TAS6417): Cullinan Oncology/Taiho Pharma
- 15.19.1. Product Description
- 15.19.2. Other Developmental Activities
- 15.19.3. Clinical Development
- 15.19.4. Safety and Efficacy
- 15.2. Patritumab Deruxtecan: Daiichi Sankyo
- 15.20.1. Product Description
- 15.20.2. Other Developmental Activities
- 15.20.3. Clinical Development
- 15.20.4. Safety and Efficacy
- 15.21. Furmonertinib: ArriVent BioPharma
- 15.21.1. Product Description
- 15.21.2. Other Developmental Activities
- 15.21.3. Clinical Development
- 15.21.4. Safety and Efficacy
- 15.22. Naptumomab Estafenatox (NAP) + Docetaxel Following Obinutuzumab: NeoTX Therapeutics
- 15.22.1. Product Description
- 15.22.2. Other Developmental Activity
- 15.22.3. Clinical Development
- 15.23. AB-16B5 + Docetaxel: Alethia Biotherapeutics
- 15.23.1. Product Description
- 15.23.2. Other Developmental Activities
- 15.23.3. Clinical Development
- 15.24. Ceralasertib: AstraZeneca
- 15.24.1. Product Description
- 15.24.2. Other Developmental Activities
- 15.24.3. Clinical Development
- 15.25. ZYNYZ (retifanlimab/INCMGA00012) + Chemotherapy: Incyte/Macrogenics
- 15.25.1. Product Description
- 15.25.2. Other Developmental Activities
- 15.25.3. Clinical Development
- 15.25.4. Safety and Efficacy
- 15.26. Gotistobart (BNT316 /ONC-392):
- 15.26.1. Product Description
- 15.26.2. Other Developmental Activities
- 15.26.3. Clinical Development
- 15.26.4. Safety and Efficacy
- 15.27. Tusamitamab ravtansine: Sanofi
- 15.27.1. Product Description
- 15.27.2. Other Developmental Activities
- 15.27.3. Clinical Development
- 15.27.4. Safety and Efficacy
- 15.28. NVL-655: Nuvalent
- 15.28.1. Product Description
- 15.28.2. Other Developmental Activities
- 15.28.3. Clinical Development
- 15.29. Ensartinib: Xcovery
- 15.29.1. Product Description
- 15.29.2. Other Developmental Activities
- 15.29.3. Clinical Development
- 15.29.4. Safety and Efficacy
- 15.3. LY3537982: Eli Lilly and Company
- 15.30.1. Product Description
- 15.30.2. Other Developmental Activities
- 15.30.3. Clinical Development
- 15.30.4. Safety and Efficacy
- 15.31. JDQ443: Novartis
- 15.31.1. Product Description
- 15.31.2. Other Developmental Activities
- 15.31.3. Clinical Development
- 15.31.4. Safety and Efficacy
- 15.32. Divarasib: Roche (Genentech)
- 15.32.1. Product Description
- 15.32.2. Other Developmental Activities
- 15.32.3. Clinical Development
- 15.32.4. Safety and Efficacy
- 15.33. RMC-4630: Revolution Medicines
- 15.33.1. Product Description
- 15.33.2. Other Developmental Activities
- 15.33.3. Clinical Development
- 15.33.4. Safety and Efficacy
- 15.34. SLATE-KRAS: Gritstone bio
- 15.34.1. Product Description
- 15.34.2. Other Developmental Activities
- 15.34.3. Clinical Development
- 15.34.4. Safety and Efficacy
- 15.35. Aumolertinib: EQRx
- 15.35.1. Product Description
- 15.35.2. Other Developmental Activity
- 15.35.3. Clinical Development
- 15.35.4. Safety and Efficacy
- 15.36. Eftilagimod alpha: Immutep/ Merck Sharp & Dohme Corp
- 15.36.1. Product Description
- 15.36.2. Other Developmental Activities
- 15.36.3. Clinical Development
- 15.36.4. Safety and Efficacy
- 15.37. Ivonescimab: Akeso Biopharma
- 15.37.1. Product Description
- 15.37.2. Other Developmental Activity
- 15.37.3. Clinical Development
- 15.37.4. Safety and Efficacy
- 15.38. Sunvozertinib: Dizal Pharmaceutical
- 15.38.1. Product Description
- 15.38.2. Other Developmental Activities
- 15.38.3. Clinical Development
- 15.38.4. Safety and Efficacy
- 16. NSCLC : 7MM Market Analysis
- 16.1. Key Findings
- 16.1.1. Total Market Size of NSCLC in the 7MM
- 16.2. Market Outlook
- 16.2.1. PD-L1 expressions
- 16.2.2. EGFR Mutation
- 16.2.3. ALK Mutation
- 16.2.4. KRAS Mutation
- 16.2.5. BRAF Mutation
- 16.2.6. MET Mutation
- 16.2.7. Others NSCLC Mutations
- 16.3. Key Market Forecast Assumptions
- 16.3.1. PD-L1-mutated NSCLC
- 16.3.2. EGFR-mutated NSCLC
- 16.3.3. ALK-mutated NSCLC
- 16.3.4. HER2-mutated NSCLC
- 16.4. United States Market Size
- 16.4.1. Total Market Size of PD-L1 NSCLC in the United States
- 16.4.2. Market Size of PD-L1 NSCLC by Therapies in the United States
- 16.4.3. Total Market Size of EGFR NSCLC in the United States
- 16.4.4. Market Size of EGFR NSCLC by Therapies in the United States
- 16.4.5. Total Market Size of ALK NSCLC in the United States
- 16.4.6. Market Size of ALK NSCLC by Therapies in the United States
- 16.4.7. Total Market Size of KRAS NSCLC in the United States
- 16.4.8. Market Size of KRAS NSCLC by Therapies in the United States
- 16.4.9. Total Market Size of ROS-1 NSCLC in the United States
- 16.4.10. Market Size of ROS-1 NSCLC by Therapies in the United States
- 16.4.11. Total Market Size of BRAF NSCLC in the United States
- 16.4.12. Market Size of BRAF NSCLC by Therapies in the United States
- 16.4.13. Total Market Size of MET NSCLC in the United States
- 16.4.14. Market Size of MET NSCLC by Therapies in the United States
- 16.4.15. Total Market Size of HER2 NSCLC in the United States
- 16.4.16. Market Size of HER2 NSCLC by Therapies in the United States
- 16.4.17. Total Market Size of RET NSCLC in the United States
- 16.4.18. Market Size of RET NSCLC by Therapies in the United States
- 16.4.19. Total Market Size of NTRK NSCLC in the United States
- 16.4.20. Market Size of NTRK NSCLC by Therapies in the United States
- 16.5. EU4 and the UK Market Size
- 16.5.1. Total Market Size of PD-L1 NSCLC in EU4 and the UK
- 16.5.2. Market Size of PD-L1 NSCLC by Therapies in EU4 and the UK
- 16.5.3. Total Market Size of EGFR NSCLC in EU4 and the UK
- 16.5.4. Market Size of EGFR NSCLC by Therapies in EU4 and the UK
- 16.5.5. Total Market Size of ALK NSCLC in EU4 and the UK
- 16.5.6. Market Size of ALK NSCLC by Therapies in EU4 and the UK
- 16.5.7. Total Market Size of KRAS NSCLC in EU4 and the UK
- 16.5.8. Market Size of KRAS NSCLC by Therapies in EU4 and the UK
- 16.5.9. Total Market Size of ROS-1 NSCLC in EU4 and the UK
- 16.5.10. Market Size of ROS-1 NSCLC by Therapies in EU4 and the UK
- 16.5.11. Total Market Size of BRAF NSCLC in EU4 and the UK
- 16.5.12. Market Size of BRAF NSCLC by Therapies in EU4 and the UK
- 16.5.13. Total Market Size of MET NSCLC in EU4 and the UK
- 16.5.14. Market Size of MET NSCLC by Therapies in EU4 and the UK
- 16.5.15. Total Market Size of HER2 NSCLC in EU4 and the UK
- 16.5.16. Market Size of HER2 NSCLC by Therapies in EU4 and the UK
- 16.5.17. Total Market Size of RET NSCLC in EU4 and the UK
- 16.5.18. Market Size of RET NSCLC by Therapies in EU4 and the UK
- 16.5.19. Total Market Size of NTRK NSCLC in EU4 and the UK
- 16.5.20. Market Size of NTRK NSCLC by Therapies in EU4 and the UK
- 16.6. Japan Market Size
- 16.6.1. Total Market Size of PD-L1 NSCLC in Japan
- 16.6.2. Market Size of PD-L1 NSCLC by Therapies in Japan
- 16.6.3. Total Market Size of EGFR NSCLC in Japan
- 16.6.4. Market Size of EGFR NSCLC by Therapies in Japan
- 16.6.5. Total Market Size of ALK NSCLC in Japan
- 16.6.6. Market Size of ALK NSCLC by Therapies in Japan
- 16.6.7. Total Market Size of KRAS NSCLC in Japan
- 16.6.8. Market Size of KRAS NSCLC by Therapies in Japan
- 16.6.9. Total Market Size of ROS-1 NSCLC in Japan
- 16.6.10. Market Size of ROS-1 NSCLC by Therapies in Japan
- 16.6.11. Total Market Size of BRAF NSCLC in Japan
- 16.6.12. Market Size of BRAF NSCLC by Therapies in Japan
- 16.6.13. Total Market Size of MET NSCLC in Japan
- 16.6.14. Market Size of MET NSCLC by Therapies in Japan
- 16.6.15. Total Market Size of HER2 NSCLC in Japan
- 16.6.16. Market Size of HER2 NSCLC by Therapies in Japan
- 16.6.17. Total Market Size of RET NSCLC in Japan
- 16.6.18. Market Size of RET NSCLC by Therapies in Japan
- 16.6.19. Total Market Size of NTRK NSCLC in Japan
- 16.6.20. Market Size of NTRK NSCLC by Therapies in Japan
- 17. Unmet Needs
- 18. SWOT Analysis
- 19. KOL Views
- 20. Market Access and Reimbursement
- 20.1. Patient Access Program
- 20.2. Institute for Quality and Efficiency in Health Care (IQWiG): Germany
- 20.3. NSCLC Reimbursement in France
- 20.4. Italian Medicines Agency (AIFA): Italy
- 20.5. NSCLC Reimbursement in Spain
- 20.6. National Institute for Health and Care Excellence (NICE): The UK
- 20.7. Reimbursement Status of Lung Cancer Drugs in Japan
- 21. Appendix
- 21.1. Bibliography
- 21.2. Report Methodology
- 22. DelveInsight Capabilities
- 23. Disclaimer
- 24. About DelveInsight
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook